Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Receivables (2022 - 2025)

Historic Receivables for Marker Therapeutics (MRKR) over the last 4 years, with Q3 2025 value amounting to $2.3 million.

  • Marker Therapeutics' Receivables rose 11688.35% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 11688.35%. This contributed to the annual value of $11.8 million for FY2024, which is 67540.17% up from last year.
  • Latest data reveals that Marker Therapeutics reported Receivables of $2.3 million as of Q3 2025, which was up 11688.35% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Receivables peaked at $8.0 billion during Q1 2025, and registered a low of $1.0 million during Q3 2024.
  • Its 4-year average for Receivables is $730.9 million, with a median of $3.1 million in 2023.
  • Data for Marker Therapeutics' Receivables shows a peak YoY increase of 26214998.92% (in 2025) and a maximum YoY decrease of 3224.98% (in 2025) over the last 5 years.
  • Quarter analysis of 4 years shows Marker Therapeutics' Receivables stood at $3.7 million in 2022, then crashed by 58.49% to $1.5 million in 2023, then surged by 675.4% to $11.8 million in 2024, then crashed by 80.88% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $3.0 million for Q2 2025, and $8.0 billion during Q1 2025.